Promoter Hypermethylation Is the Predominant Mechanism in \textit{hMLH1} and \textit{hMSH2} Deregulation and Is a Poor Prognostic Factor in Nonsmoking Lung Cancer

Han-Shui Hsu,\textsuperscript{1,3} Chiao-Kai Wen,\textsuperscript{4} Yen-An Tang,\textsuperscript{4} Ruo-Kai Lin,\textsuperscript{4} Wing-Yin Li,\textsuperscript{2} Wen-Hu Hsu,\textsuperscript{1} and Yi-Ching Wang\textsuperscript{4}

**Abstract**

Purpose and Experimental Design: The etiologic association and prognostic significance of mismatch repair gene/protein alterations have never been examined in nonsmoking lung cancer. Therefore, we investigated protein expression and promoter hypermethylation of \textit{hMLH1} and \textit{hMSH2} genes in the tumor specimens from 105 nonsmoking female non–small cell lung cancer (NSCLC) patients. Immunohistochemistry and restriction enzyme–based multiplex PCR were used to examine the protein expression and promoter hypermethylation, respectively. The occurrence of gene/protein alteration for each gene was compared with the patients’ clinicopathologic variables as well as the overall survival and cancer-specific survival rates.

Results: Protein expression alteration and promoter hypermethylation were observed in 66\% to 67\% and 30\% to 34\% of specimens for \textit{hMLH1} and \textit{hMSH2} genes, respectively. Loss of \textit{hMLH1} and \textit{hMSH2} protein expression was significantly associated with their promoter hypermethylation ($P < 0.0001$ and $P = 0.049$). The overall survival and cancer-specific survival rates were significantly lower in patients with promoter hypermethylation of \textit{hMSH2} gene than in those without hypermethylation ($P = 0.038$ and $P = 0.004$). The poor prognosis was still especially significant in adenocarcinoma ($P = 0.035$ and $P = 0.061$) and early-stage NSCLC patients ($P = 0.067$ and $P = 0.041$).

Conclusion: Our data suggest that \textit{hMLH1} is the major altered mismatch repair gene involved in nonsmoking NSCLC tumorigenesis and that promoter methylation is the predominant mechanism in \textit{hMLH1} and \textit{hMSH2} deregulation. In addition, promoter methylation of the \textit{hMSH2} gene may be a potential prognostic factor in nonsmoking female lung cancer.

Lung cancer has become the leading cause of cancer death in many industrialized countries; in Taiwan, lung cancer claims >7,000 lives annually (1). In recent years, much attention has been focused on the rapidly increasing incidence of primary lung cancer in nonsmoking patients (2–4). Some gender differences exist in the distribution of lung cancer, including histologic type and exposure to tobacco (5–9). Although 80\% of female lung cancer patients worldwide have smoked, <10\% of Taiwanese women with lung cancer have ever smoked. The low smoking status and high incidence rate of adenocarcinoma constitute distinctive characteristics of Taiwanese female lung cancers. Ryberg et al. showed that susceptibility to DNA damage caused by environmental carcinogens such as polycyclic aromatic hydrocarbon–like compounds may be higher among women than among men. They concluded that women are at greater risk of tobacco and/or environmental-induced lung cancer (10). In the study of Takagi et al., distinct mutational spectrum of the p53 gene in lung cancer tissues from nonsmoking Chinese women in Hong Kong was observed, suggesting that environmental and/or genetic factors might be involved in the development of lung cancer in women (11).

Molecular biological studies have shown that overt cancers carry multiple genetic and epigenetic alterations, indicating inactivation of tumor suppressor genes and activation of dominant oncogenes during the process of carcinogenesis and subsequent progression of cancers (12, 13). Alteration analysis in the genes controlling acquired somatic mutations, such as genes involved in the DNA repair system, may explain some of the observed significance in susceptibility to various conditions caused by environmental factors in nonsmoking female lung cancer. \textit{hMLH1} and \textit{hMSH2} are two of the genes known to be implicated in the DNA mismatch repair system. Inactivation of these two genes by promoter hypermethylation has been reported to be associated with some human cancers (14–18). Herman et al. suggested that DNA methylation associated with...
transcriptional silencing of hMLH1 is the underlying cause of mismatch repair defects in most sporadic colorectal cancers (14). Xinarianos et al. have shown that 58.6% and 57.8% of lung cancer tumor specimens had reduced expression levels of the hMLH1 and hMSH2 proteins, respectively (19). However, the distribution of the gender related to the protein expression of the genes was not mentioned in the article. In addition, the clinical significance of the protein expression of hMLH1 and hMSH2 in nonsmoking lung cancers remains unclear. Recently, Brooks et al. reported that in patients with stage III non–small cell lung cancer (NSCLC), low protein expression of hMSH2 in the positive mediastinal nodal specimens was associated with poor treatment response and cancer death (20). In the previous report from our laboratory, we examined the protein expression and the status of promoter hypermethylation of hMLH1 and hMSH2 genes in 77 NSCLC tumors and found that protein expression of hMLH1 and hMSH2 in the tumor specimens from female patients with lung cancer was higher than in specimens from male patients, although only a few female tumor samples were examined (21). Following this finding, the present study collected more tumor specimens, focusing on nonsmoking female NSCLC patients, to investigate the protein expression of hMLH1 and hMSH2 and promoter hypermethylation of these two genes in these tumor tissues. The clinical association and prognostic significance of both genes in the nonsmoking female patients with lung cancer were also analyzed.

Materials and Methods

Study population and tumor samples. From 1996 to 1998, 105 nonsmoking female patients who had operations for NSCLC were enrolled in this study. The demographic data of these patients including the smoking habit, age, tumor type, and the stage of disease were collected by chart review. There was complete follow-up for all patients. The end of the follow-up period was defined as October 2004. Overall survival was calculated from the day of surgery to the date of death or the last follow-up. Cancer-specific survival was calculated from the day of surgery to the date of either lung cancer death or the last follow-up. The mean follow-up period for all patients was 32 months (range, 0.5–78 months). Of 105 patients, 42 (40%) patients died from lung cancer and had a median cancer-specific survival of 17 months (range, 0.5–44 months).

Analysis of protein expression: immunohistochemistry assay. Paraffin blocks of tumors were cut into 5-μm slices and then processed using protocols described in our previous publication (21). hMLH1 and hMSH2 protein expression was evaluated by the immunohistochemistry assay. The monoclonal antibodies used were G168-728 (1:250; Oncogene Science, Cambridge, MA) for the hMSH2 protein, and FE11 (1:50; PharMingen, San Diego, CA) for the hMLH1 protein and CL-2 and CL1-5-F4 lung cancer cell line was included in each analysis. Aberrant hMLH1 protein expression was significantly associated with promoter hypermethylation of hMLH1 protein (45.5%) than those with clinicopathologic variables in female patients with lung cancer.

Restriction enzyme–based multiplex PCR methylation assay. The promoter methylation status of the hMLH1 and hMSH2 genes was investigated using the HpaII/HhaI and HhaI-based restriction enzyme–based PCR (RE-PCR) analysis, respectively. The hMLH1 promoter region (−670 to −67) contains four HpaII sites and two HhaI sites, whereas there are four HhaI sites for the hMSH2 promoter region (−354 to −126). Genomic DNA (200 ng) was digested either with 10 units of the methylation-sensitive enzyme (HhaI and/or HpaII, New England Biolabs, Beverly, MA) or placed in the appropriate buffer without enzyme for 10 hours at 37°C. The DNA was subjected to a second round of digestion by another 10 units of freshly added enzymes to improve specificity and completeness of digestion. The digested DNA was purified by phenol/chloroform extraction followed by ethanol precipitation. One hundred nanograms of the digested DNA was subjected to the multiplex PCR. The primer nucleotide sequences for the hMLH1 promoter region and an internal control D33S3281 sequence, which contains no HpaII and HhaI sites, were reported previously (21). The primer nucleotide sequences for the hMSH2 gene were sense 5′-GGTCCTCTCTGATGTTACTCC-3′ and antisense 5′-CCGCCGCACCGCCTGGTC-3′. Methylation was determined by the ratio of the normalized intensity (target gene/internal control) of the samples pretreated with digested (+) over the undigested (−) samples. DNA of 30 normal lung tissues from NSCLC patients was examined; the ratio was <0.2 for all samples examined. Therefore, a ratio of >0.2 was defined as aberrant methylation. DNA from normal lymphocytes as well as CL2 and CL1-5-F4 lung cancer cell line was included in each assay to serve as unmethylated and methylated controls, respectively, of the hMLH1 and hMSH2 genes.

Results

Genetic alterations of hMLH1 protein/gene and its correlation with clinicopathologic variables in nonsmoking female patients with lung cancer. Immunohistochemical staining for hMLH1 protein was done on 105 tumor samples. Staining within the nucleus of tumor cells was considered positive. Thirty-five lung tumors showed staining of moderate to strong intensity (Fig. 1A). The remaining 70 tumor cancer specimens showed a complete absence of nuclear staining of hMLH1 protein (66.7%; Fig. 1B and C). There was no significant correlation between the hMLH1 protein expression and age, smoking habit, tumor cell type, and tumor stage (Table 1). RE-PCR methylation assay indicated that 70 of these 105 tumor specimens showed promoter hypermethylation of hMLH1 gene (66.7%; Fig. 2A). Analysis of the relationship between the expression of hMLH1 protein and its promoter hypermethylation was done. Aberrant hMLH1 protein expression was significantly associated with promoter hypermethylation of hMLH1 gene (p < 0.0001; Table 1).

Genetic alterations of hMSH2 protein/gene and its correlation with clinicopathologic variables in female patients with lung cancer. Seventy-four tumor specimens showed moderate to strong staining of hMSH2 protein (Fig. 1D). The remaining 31 lung cancer specimen showed a complete absence of nuclear staining of hMSH2 protein (29.5%; Fig. 1E and F). There was also no significant correlation between the hMSH2 protein expression and patients’ age, smoking habit, tumor cell type, and tumor stage (Table 2). Thirty-six of these 105 tumor specimen showed promoter hypermethylation of the hMSH2 gene (34.3%; Fig. 2B). The tumor specimens of late-stage (stages III and IV) patients displayed more promoter hypermethylation of the hMSH2 gene (45.5%) than those.
early-stage patients (26.2%; \( P = 0.041 \)). The aberrant hMSH2 protein expression was significantly associated with promoter hypermethylation of the \( hMSH2 \) gene (\( P = 0.049 \); Table 2).

**Correlation of \( hMLH1 \) and \( hMSH2 \) alterations with the prognosis of nonsmoking female non–small cell lung cancer patients.** The relationship between survival and the alteration of \( hMLH1 \) and \( hMSH2 \) was analyzed (Fig. 3). The \( hMLH1 \) protein expression and DNA hypermethylation were not significantly associated with the prognosis of female patients with lung cancer. However, the overall survival and cancer-specific survival rates were significantly lower in patients with promoter hypermethylation of \( hMSH2 \) gene than in those without promoter hypermethylation (Fig. 3A, \( P = 0.038 \); Fig. 3B, \( P = 0.004 \)). In patients with early stage and without lymph node metastasis, the overall survival and cancer-specific survival were also significantly lower in patients with promoter hypermethylation of \( hMSH2 \) than in patients without promoter hypermethylation (Fig. 3C and D, \( P = 0.067 \) and \( P = 0.041 \) for the early-stage patients; Fig. 3E and F, \( P = 0.211 \) and \( P = 0.007 \) for the patients without lymph node metastasis). In patients with adenocarcinoma of the lung but not with squamous carcinoma, the overall survival and cancer-specific survival were significantly low in patients with promoter hypermethylation of \( hMSH2 \) (Fig. 3G and H, \( P = 0.035 \) and \( P = 0.061 \)). The data indicated that for female patients, promoter hypermethylation of \( hMSH2 \) was associated with a poorer prognosis.

**Discussion**

In this study, the significance of the DNA mismatch repair genes, \( hMLH1 \) and \( hMSH2 \), in nonsmoking female NSCLC patients was investigated by analysis of protein expression and promoter methylation of the \( hMLH1 \) and \( hMSH2 \) genes in 105 tumor specimens. Protein expression alteration and promoter hypermethylation were observed in 66% to 67% and 30% to 34% of tumor specimens for the \( hMLH1 \) and \( hMSH2 \) genes, respectively. A significant concordance was observed between the alterations in protein and DNA hypermethylation of both genes, suggesting that promoter hypermethylation is the predominant mechanism in \( hMLH1 \) and \( hMSH2 \) deregulation. Note that promoter hypermethylation of \( hMSH2 \) was significantly associated with poor prognosis in these nonsmoking female NSCLC patients, especially in the case of adenocarcinoma and early-stage patients. The registry data indicate that most of the female patients with lung cancer did not smoke and that adenocarcinoma was the predominant tumor cell type in
all patients with NSCLC in Taiwan. The importance of identifying factors that increase the risk of lung adenocarcinomas in nonsmoking females has long been recognized. To our knowledge, comprehensive molecular and clinical analyses on the alterations of hMLH1 and hMSH2 in nonsmoking lung cancer patients to reveal the contribution of mismatch repair inactivation to NSCLC tumorigenesis have never been reported. This is also the first report of an association of hMSH2 promoter

Table 1. Genetic alterations of hMLH1 protein/gene in relation to the clinicopathologic variables of resected nonsmoking female lung cancer tumors

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Protein expression</th>
<th>DNA hypermethylation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>Total +</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>105</td>
<td>35</td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
<td>61.2 ± 11</td>
<td>59.4 ± 13</td>
</tr>
<tr>
<td>Age &lt;60</td>
<td>57</td>
<td>22</td>
</tr>
<tr>
<td>≥60</td>
<td>48</td>
<td>13</td>
</tr>
<tr>
<td>Tumor type</td>
<td>AD</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>SQ</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>AS</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>21</td>
</tr>
<tr>
<td>Tumor stage</td>
<td>I + II</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>III + IV</td>
<td>44</td>
</tr>
<tr>
<td>Protein expression</td>
<td>+</td>
<td>35</td>
</tr>
</tbody>
</table>

Abbreviations: AD, adenocarcinoma; SQ, squamous carcinoma; AS, adenosquamous carcinoma.
*These groups represent patients with alteration in the hMLH1 gene/protein.
†The comparison was made between SQ and AD.

Table 2. Genetic alterations of hMSH2 protein/gene in relation to the clinicopathologic variables of resected nonsmoking female lung cancer tumors

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Protein expression</th>
<th>DNA hypermethylation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>Total +</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>105</td>
<td>69</td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
<td>60.5 ± 12</td>
<td>58.9 ± 13</td>
</tr>
<tr>
<td>Age &lt;60</td>
<td>57</td>
<td>41</td>
</tr>
<tr>
<td>≥60</td>
<td>48</td>
<td>33</td>
</tr>
<tr>
<td>Tumor type</td>
<td>AD</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>SQ</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>AS</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td>21</td>
</tr>
<tr>
<td>Tumor stage</td>
<td>I + II</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>III + IV</td>
<td>44</td>
</tr>
<tr>
<td>Protein expression</td>
<td>+</td>
<td>74</td>
</tr>
</tbody>
</table>

Abbreviations: AD, adenocarcinoma; SQ, squamous carcinoma; AS, adenosquamous carcinoma.
*These groups represent patients with alteration in the hMSH2 gene/protein.
†The comparison was made between SQ and AD.
Fig. 3. Overall survival (OS) and cancer-specific survival (CS) of all nonsmoking female NSCLC patients (A-B), early-stage nonsmoking female patients (C-D), nonsmoking female patients without lymph node metastasis (E-F), nonsmoking female adenocarcinoma patients (G-H), and nonsmoking female squamous patients (I-J) according to the results of hMSH2 promoter hypermethylation. P value for each analysis is also indicated.
hypermethylation with prognosis in nonsmoking female NSCLC patients.

The data on mismatch repair gene alterations in lung cancer is scarce. Xinarianos et al. previously reported the expression levels of hMLH1 and hMSH2 proteins in the tumor specimens from 59 males and 91 female patients with lung cancer in the United Kingdom and showed that 53% and 82% of adenocarcinoma specimens of both male and female had reduced expression levels of the hMLH1 and hMSH2 protein, respectively (19). Supporting the results of our study, Xinarianos et al. have also reported a high frequency of reduced expression levels of the hMLH1 protein. However, the expression level of hMSH2 protein in their study was apparently higher than in our study. In contrast to our study, which focused on nonsmoking female NSCLC, there were only six nonsmokers in their study. In addition, the promoter methylation status was not examined in their study. A study by Aubry et al. showed by immunohistochemistry assay that mismatch repair proteins hMLH1, hMSH2, and hMSH6 were not inactivated in 33 bronchioalveolar carcinomas of the lung (22). This type of inconsistency also occurred in a U.S. study, which found no promoter methylation of the hMLH1 gene in 20 NSCLC tumors by the methylation-specific PCR (MSP) assay (23). In the study of small cell lung cancer, Hansen et al. showed that low hMLH1 protein expression was not linked to promoter methylation in a panel of 21 small cell lung cancer cell lines using the MSP assay (24). The discrepancy may be due to the patients with different clinicopathologic variables examined in the contrasting studies. For example, there were more patients who were nonsmoking female adenocarcinoma lung cancer patients in our study compared with previous studies. Alternatively, the methylation regions examined and sensitivities of the assay used in various studies were different. It is also possible that geographic and/or ethnic factors account for frequent hMLH1 and hMSH2 alterations in Taiwanese NSCLC patients. In addition, environmental factor(s) other than cigarette smoke and/or endogenous factor(s) may be involved in the observed association of hMLH1 and hMSH2 alterations with nonsmoking female adenocarcinomas.

Some authors suggested that a relationship exists between the expression of hMLH1 and hMSH2 protein and drug resistance or the response to therapy including chemotherapy or radiotherapy for cancer patients (20, 25, 26). Strathdee et al. investigated the role of methylation of hMLH1 in drug resistance in ovarian cancer cell lines and suggested that methylation of the hMLH1 promoter may be a common mechanism for cisplatin resistance in ovarian cancer (25). In addition, Mackay et al. reported that reduction of hMLH1 protein expression in breast tumor samples after chemotherapy was strongly associated with poor disease-free survival (26). Note that Brooks et al. investigated the expression of hMSH2 in the positive mediastinal nodal specimens of 59 NSCLC patients with stage III diseases who were treated with chemotherapy and irradiation therapy and found that low expression of hMSH2 was associated with poor overall survival (20). In our study, we also found that there was a relationship between the promoter hypermethylation of hMSH2 gene and the poor prognosis of the nonsmoking female NSCLC patients. In the patients with early-stage lung cancer and without lymph node metastasis, in whom clinical oncologists need selection factors to decide whether adjuvant therapy is necessary, the patients with promoter hypermethylation of hMSH2 had a poorer cancerspecific survival than those without DNA hypermethylation. To the best of our knowledge, this is the first study showing a relationship between the status of hMSH2 promoter hypermethylation and the prognosis of patients with lung cancer. How the expression of hMLH1 or hMSH2 could influence the results of chemotherapy or radiotherapy is a question that warrants further analysis.

The inactivation of DNA mismatch repair gene has been mentioned as being associated with the genetic instability of some cancers. Loss of hMLH1 expression was shown as one of the main causes of microsatellite instability in colorectal cancer (16, 18). Selective defect in some mismatch repair genes can cause genomic instability and activate the malignant transformation as well as the progression of gastric cancer, renal cell carcinoma, and endometrial carcinoma (15, 17, 27). In our previous article, we had indicated that aberrant methylation, which can result in the transcriptional silencing of the target gene, was frequently found in the hMLH1 alterations and microsatellite instability in NSCLC tumors (28). A highly significant correlation was found between gene methylation and negative protein expression for mismatch repair hMLH1 and hMSH2 genes, suggesting that promoter hypermethylation is the predominant mechanism by which these two mismatch repair genes are silenced in NSCLC. This may eventually lead to genetic instability and poorer prognosis of lung cancer. However, Ward et al. (29) reported that poor prognostic effect of DNA methylation is lost in colorectal patients with microsatellite instability. It seems that methylated tumors, both unstable and stable, have distinct clinicopathologic features, which warrants further analysis in nonsmoking lung cancer. Mechanisms involving DNA damage signaling, promoter hypermethylation of mismatch repair genes, and the target drug-resistant genes after chemotherapy are also under investigation.

References
15. Leung SY, Yuen ST, Chung LP, Chu KM, Chan ASY, Ho JCL. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 1999;59:159–64.
Promoter Hypermethylation Is the Predominant Mechanism in \textit{hMLH1} and \textit{hMSH2} Deregulation and Is a Poor Prognostic Factor in Nonsmoking Lung Cancer

Han-Shui Hsu, Chiao-Kai Wen, Yen-An Tang, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/11/15/5410

Cited articles
This article cites 25 articles, 12 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/11/15/5410.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/11/15/5410.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.